A licence suspension has been addressed by the Bombay high court. The court has instructed the FDA to revoke the suspension once certain deficiencies are rectified.

The order indicates that the suspension was likely due to specific issues that need to be resolved. Details about the nature of the deficiencies and the entity affected by the licence suspension are not provided here.

Further information about the case and the court's decision can be found in the source publication, which may offer additional context and details about the situation and the parties involved.